A quorum was present and Ms. Lisa Ashworth, Chair pro tem, presided over the Compounding Expert Committee (CMP EC) meeting. The following is a summary of the actions and key discussion topics that impacted the work of the CMP EC, grouped by topic.

1. **General Chapter <797> Pharmaceutical Compounding–Sterile Preparations**: Proposed revisions to General Chapter <797> will be pre-posted on USP.org on September 25, 2015, and published in *PF 41*(6) [Nov.-Dec. 2015] for public comment. The 2010–2015 CMP EC worked closely with government liaisons, including those from the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention, and the General Chapters–Microbiology EC on the revisions. The following is a timeline of related, upcoming activities:
   - September 25, 2015—Pre-posting of <797> on USP.org
   - October 21, 2015, 2:00–4:00 p.m. EST—Open microphone Webinar
   - November 2, 2015—Publication in *PF 41*(6)
   - January 31, 2016—End of public comment period

2. **General Chapter <800> Hazardous Drugs–Handling in Healthcare Settings**: EC members discussed this new General Chapter that will be on the October 2015 ballot for publication in *USP 39–NF 34, First Supplement*. The EC discussed a delayed official implementation in order to give practitioners and facilities time to come into compliance.

3. **General Chapter <1168> Compounding for Investigational Studies**: USP staff presented an overview of this General Chapter, and EC members and FDA liaisons discussed its intent and scope. FDA liaisons will participate on the <1168> Subcommittee to address legal and regulatory issues.

4. **Fiscal Year (FY) 2016 Monograph Development**: EC members provided feedback on the Technical Proposal that explains the scope of work for contract laboratories to conduct stability studies for compounded preparation monographs. EC members also suggested compounded preparation monograph candidates for FY 2016 stability studies. USP staff and the Monograph Development Subcommittee will finalize the list of monograph candidates for the FY 2016 studies.

5. **Completed Stability Studies**: USP staff reported that stability studies for 15 compounded preparation monographs from FY 2014 and FY 2015 were successfully completed. The Monograph Development Subcommittee will review the results and develop the monographs for publication in *Pharmcpeial Forum* for public comment.

6. **Subcommittees**: The EC formed the following Subcommittees to work on activities related to the development and revision of general chapters and monographs.
   - <795> *Pharmaceutical Compounding–Nonsterile Preparations* Subcommittee
   - <797> *Pharmaceutical Compounding–Sterile Preparations* Subcommittee
   - <800> *Hazardous Drugs–Handling in Healthcare Settings* Subcommittee
   - <1163> *Quality Assurance in Pharmaceutical Compounding* Subcommittee
   - <1168> *Compounding for Investigational Studies* Subcommittee
   - Monograph Development Subcommittee